Skip to main content
SpringerLink
Log in

Clinical Significance of the Upregulated Osteopontin mRNA Expression in Human Colorectal Cancer

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Objective

Osteopontin (OPN) is a phosphorylated glycoprotein which is associated with tumor progression, development, and metastasis. Recently, it has been reported that OPN is highly upregulated in a variety of human malignancies. The aim of this study is to investigate the clinical significance of OPN mRNA expression in colorectal cancer (CRC).

Material and Methods

Conventional reverse transcription polymerase chain reaction (RT-PCR) and Western blot assays were performed to detect the expression of OPN mRNA and protein in human CRC cell lines and normal cell line. Real-time quantitative RT-PCR assay was performed to analyze the expression of OPN mRNA in 82 CRC tissue samples and corresponding non-tumor tissues. Immunohistochemistry was also performed to detect the expression of OPN protein in above tissues. Finally, the correlation between the status of OPN mRNA expression and clinicopathological factors and clinical outcome was evaluated.

Results

Compared with normal human intestinal epithelial cell line, human CRC cell lines showed high level of OPN gene expression at both transcriptional and translational levels. Moreover, the results of real-time quantitative RT-PCR and immunohistochemistry showed that the expression levels of OPN mRNA and protein in tumor tissues were significantly higher than those in the corresponding non-tumor tissues (P < 0.001). The expression level of OPN mRNA was significantly correlated with lymph node metastasis, lymphatic or venous invasion, and TNM stage (P = 0.0033, 0.0061, 0.0008, and 0.0012, respectively). Moreover, we also observed that the disease-free and overall survival rates in patients with high OPN mRNA expression were significantly shorter than those in patients with low OPN mRNA expression (P = 0.0047 and 0.0125). Additionally, the status of OPN mRNA expression was an independent prognostic factor for the prognosis of CRC patients (P = 0.008; RR, 2.775; 95% confidence interval, 2.334–3.811).

Conclusion

OPN might play an important role in CRC progression and the status of OPN mRNA expression could be a novel prognostic molecular marker for CRC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–130.

    Article  PubMed  Google Scholar 

  2. Siegel RL, Jemal A, Thun MJ, Hao Y, Ward EM. Trends in the incidence of colorectal cancer in relation to county-level poverty among blacks and whites. J Natl Med Assoc 2008;100:1441–1444.

    PubMed  Google Scholar 

  3. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000;11:279–303.

    Article  CAS  PubMed  Google Scholar 

  4. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 2001;41:723–749.

    Article  CAS  PubMed  Google Scholar 

  5. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997;17:1–15.

    CAS  PubMed  Google Scholar 

  6. Denhardt DT, Lopez CA, Rollo EE, Hwang SM, An XR, Walther SE. Osteopontin-induced modifications of cellular functions. Ann N Y Acad Sci 1995;760:127–142.

    Article  CAS  PubMed  Google Scholar 

  7. Weber GF, Ashkar S, Cantor H. Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians 1997;109:1–9.

    CAS  PubMed  Google Scholar 

  8. Hu Z, Xiao T, Lin DM, Guo SP, Zhang ZQ, Di XB, Cheng SJ, Gao YN. Over-expression of osteopontin in non-small cell lung cancers: its clinical significance. Zhonghua Zhong Liu Za Zhi 2007;29:591–595.

    CAS  PubMed  Google Scholar 

  9. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mänsson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1087–1097.

    Article  CAS  PubMed  Google Scholar 

  10. Wu IC, Wu MT, Chou SH, Yang SF, Goan YG, Lee JM, Chou YP, Bair MJ, Wang TE, Chen A, Chang WH, Kuo FC, Wu DC. Osteopontin expression in squamous cell cancer of the esophagus. World J Surg 2008;32:1989–1995.

    Article  PubMed  Google Scholar 

  11. Cho H, Kang ES, Kim YT, Kim JH. Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest 2009;27:313–323.

    Article  CAS  PubMed  Google Scholar 

  12. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 2007;14:3419–3427.

    Article  PubMed  Google Scholar 

  13. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928–2935.

    Article  CAS  PubMed  Google Scholar 

  14. Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J, Li K, Tong X, Dai J, Yao S, Wu M, Guo Y. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008;135:956–968.

    Article  CAS  PubMed  Google Scholar 

  15. Muramatsu T, Shima K, Ohta K, Kizaki H, Ro Y, Kohno Y, Abiko Y, Shimono M. Inhibition of osteopontin expression and function in oral cancer cell lines by antisense oligonucleotides. Cancer Lett 2005;217:87–95.

    Article  CAS  PubMed  Google Scholar 

  16. Irby RB, McCarthy SM, Yeatman TJ. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 2004;21:515–523.

    Article  CAS  PubMed  Google Scholar 

  17. Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F. Prognostic factors in colorectal cancer: literature review for clinical application. Dis Colon Rectum 1998;41:1033–1049.

    Article  CAS  PubMed  Google Scholar 

  18. Lee IK, Kim do H, Gorden DL, Lee YS, Sung NY, Park GS, Kim HJ, Kang WK, Park JK, Ahn CH, Kim JG, Jeon HM, Oh ST. Prognostic value of CEA and CA 19–9 tumor markers combined with cytology from peritoneal fluid in colorectal cancer. Ann Surg Oncol 2009;16:861–870.

    Article  PubMed  Google Scholar 

  19. Cardella J, Coburn NG, Gagliardi A, Maier BA, Greco E, Last L, Smith AJ, Law C, Wright F. Compliance, attitudes and barriers to post-operative colorectal cancer follow-up. J Eval Clin Pract 2008;14:407–415.

    Article  PubMed  Google Scholar 

  20. Song G, Cai QF, Mao YB, Ming YL, Bao SD, Ouyang GL. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Sci 2008;99:1901–1907.

    CAS  PubMed  Google Scholar 

  21. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008;27:103–118.

    Article  CAS  PubMed  Google Scholar 

  22. Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, Shimono M. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Oral Pathol Med 2007;36:30–34.

    CAS  PubMed  Google Scholar 

  23. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009;17:153–161.

    Article  CAS  PubMed  Google Scholar 

  24. Zhu XQ, Ye QH, Lei KF, Chen J, Qin LX. Knocking down osteopontin expression by specific siRNA reduces the in vitro invasiveness of human hepatocellular carcinoma cells. Zhonghua Zhong Liu Za Zhi 2006;28:404–407.

    CAS  PubMed  Google Scholar 

  25. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, Qin LX. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008;48:1834–1842.

    Article  CAS  PubMed  Google Scholar 

  26. Zagani R, Hamzaoui N, Cacheux W, de Reyniès A, Terris B, Chaussade S, Romagnolo B, Perret C, Lamarque D. Cyclooxygenase 2 inhibitors downregulate osteopontin and Nr4a2-new therapeutic targets for colorectal cancers. Gastroenterology 2009 Jun 20. [Epub ahead of print]

  27. Yeatman TJ, Chambers AF. Osteopontin and colon cancer progression. Clin Exp Metastasis 2003;20:85–90.

    Article  CAS  PubMed  Google Scholar 

  28. Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR, Janssen KP. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer 2007;121:1717–1723.

    Article  CAS  PubMed  Google Scholar 

  29. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 2005;26:741–751.

    Article  CAS  PubMed  Google Scholar 

  30. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513–521.

    CAS  PubMed  Google Scholar 

  31. Finke J, Fritzen R, Ternes P, Lange W, Dölken G. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. Biotechniques 1993;14:448–453.

    CAS  PubMed  Google Scholar 

  32. Stanta G, Schneider C. RNA extracted from paraffin-embedded human tissues is amenable to analysis by PCR amplification. Biotechniques 1991;11:304–308.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry

Author information

Authors and Affiliations

  1. Department of Infection, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China

    Wang Likui, Wang Hong & Zhang Shuwen

Authors
  1. Wang Likui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wang Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhang Shuwen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wang Likui.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Likui, W., Hong, W. & Shuwen, Z. Clinical Significance of the Upregulated Osteopontin mRNA Expression in Human Colorectal Cancer. J Gastrointest Surg 14, 74–81 (2010). https://doi.org/10.1007/s11605-009-1035-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-009-1035-z

Keywords

Search

Navigation